全球MASLD研究:纤维化、临床事件与死亡的预测因素
全球MASLD(G-MASLD)队列纳入17792例活检确诊的MASLD患者,35%存在进展期纤维化(≥F3),2型糖尿病(T2D)患病率随纤维化分期从F0的28%升至F4的70%。中位随访6.6年期间6.5%死亡、10.1%发生临床事件,组织学纤维化与无创纤维化标志物(NITs)均为死亡和肝脏相关结局的独立预测因素。
要点
- 活检确诊MASLD患者中35%存在进展期纤维化(≥F3),T2D患病率随纤维化分期递增。
- 年龄、T2D、肥胖为进展期纤维化的独立预测因素,肥胖关联存在地区差异。
- 组织学纤维化与NITs均独立预测死亡和临床事件,支持NITs用于预后评估。
核心结论
- 在大型全球活检确诊MASLD队列中,进展期纤维化患病率高且与T2D强相关。
- 组织学纤维化和NITs均为死亡与临床结局的独立预测因素,凸显NITs评估纤维化的预后价值。
研究设计与样本
- 全球MASLD(G-MASLD)研究纳入活检确诊的MASLD患者,收集临床、组织学和无创检测(NIT)数据。
- 共17792例MASLD患者,评估进展期组织学纤维化(F3-F4)相关因素及临床结局,随访平均6.6年。
主要发现
- 进展期纤维化(≥F3)占35%,T2D患病率从F0的28%逐步升至F4的70%(趋势p<0.0001)。
- 进展期纤维化的独立预测因素包括年龄较大、T2D和肥胖,但肥胖关联因地区而异。
- 随访期间6.5%死亡、10.1%发生临床事件;年龄较大、男性、T2D和肥胖均为死亡与临床事件的独立预测因素(p<0.05)。
- 纤维化严重程度(组织学或NITs定义)与死亡和肝脏相关结局风险升高强相关(所有校正HR>1.0,p<0.001)。
- 总体5年死亡率为2.1%,肝硬化患者升至8.3%,高风险NIT评分值者超过10%。
临床怎么用
- 在MASLD患者中应评估纤维化严重程度,组织学与NITs均可用于死亡和肝脏结局的风险分层。
- 对合并T2D、肥胖或年龄较大的MASLD患者需警惕进展期纤维化,并加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Advanced histologic fibrosis is a major predictor of mortality in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to identify advanced fibrosis clinical determinants across diverse MASLD populations and to assess the prognostic value of noninvasive markers (NITs) of fibrosis for adverse outcomes. APPROACH AND RESULTS: The Global MASLD (G-MASLD) enrolled biopsy-confirmed MASLD patients with clinical, histologic, and noninvasive test (NIT) data. Factors associated with the presence of advanced histologic fibrosis (F3-F4) in MASLD and clinical outcomes were assessed. There were 17,792 patients with MASLD. Advanced fibrosis (≥F3) was present in 35%. The prevalence of type 2 diabetes (T2D) increased stepwise with fibrosis stage, from 28% in F0 to 70% in F4 (trend p <0.0001). Independent predictors of advanced fibrosis included older age, T2D, and obesity, although the association with obesity varied by region. Among patients with follow-up (mean 6.6 y), 6.5% died and 10.1% experienced a clinical event. Older age, male sex, T2D, and obesity were independent predictors of both mortality and clinical events ( p <0.05). Fibrosis severity, whether defined histologically or by NITs, was strongly associated with higher risks of death and liver-related outcomes (all adjusted HR>1.0, p <0.001). Five-year mortality was 2.1% overall, rising to 8.3% in patients with cirrhosis, and exceeded 10% among those with high-risk NIT score values. CONCLUSIONS: In this large global biopsy-based MASLD cohort, advanced fibrosis was highly prevalent and strongly linked to T2D. Both histologic fibrosis and NITs were independent predictors of mortality and clinical outcomes, underscoring the prognostic value of fibrosis assessment with NITs.
引用
- Younossi ZM, de Avila L, Petta S, et al. Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study. Hepatology. 2025. PMID: 41231627. doi:10.1097/HEP.0000000000001617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。